Antibody-Mediated Rejection After Lung Transplantation

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


An important role for donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) in lung allograft rejection has been recognized since the late 1990s. Early studies identified the development of HLA antibodies as a risk factor for chronic rejection. Recently, antibody-mediated rejection (AMR) has been increasingly recognized as a form of lung allograft rejection, and the International Society for Heart and Lung Transplantation proposed a consensus definition. However, experience with AMR after lung transplantation remains limited, and outcomes are poor with many patients dying of AMR or developing progressive chronic rejection after the diagnosis.

Original languageEnglish
Title of host publicationEncyclopedia of Respiratory Medicine, Second Edition
Number of pages6
ISBN (Electronic)9780081027240
ISBN (Print)9780081027233
StatePublished - Jan 1 2021


  • Antibody-mediated rejection
  • Bronchiolitis obliterans syndrome
  • Chronic lung allograft dysfunction
  • Donor-specific antibodies
  • Human leukocyte antigens
  • Immunosuppression
  • Lung transplantation
  • Outcomes
  • Restrictive allograft syndrome
  • Survival


Dive into the research topics of 'Antibody-Mediated Rejection After Lung Transplantation'. Together they form a unique fingerprint.

Cite this